Mbd2 drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition.
In many cancers, high MBD2 expression is associated with poor prognosis, indicating a more aggressive tumor phenotype and potential resistance to therapy. This is often due to its role in silencing tumor suppressor genes through DNA methylation.
(Will delete Record if Target field = "Delete") Home